"Overall Rationale for the Amendment:\nAmendment 02 is a global amendment to include details about\nand the use of blinded interim data to complete a psychometric analysis\nCCI\nof the Asthma Daily/Nightly Symptom Diary (ADSD/ANSD) and CCI\nAdditional changes include repeated spirometry assessment and/or additional lab test if\nrandomisation\ncriteria\nare not met during screening, change in the ratio of medium/high\nICS dose, allowance/permittance of authorized COVID-19 treatments, Global Initiative\nfor Asthma (GINA) inhaled corticosteroid (ICS) doses update, and QT prolongation\nclarifications.\nAdded note for exclusion of adolescents in Germany, United Kingdom\n(UK), Russia.\nText added related to special procedure for the urinalysis in China sites.",
"Overall Rationale for the Amendment: Amendment 01 is a global amendment to\ninclude modifications based on regulatory suggestion and additional changes were\nincorporated which align with program revisions and/or updates as listed in table below.\nTerm “Clinic” modified to “Study”\nBrief Rationale\nModification with respect to the\nplanned open label extension\nstudy\nDue to the inclusion of an ECG\nat week 2 and week 28 these\nvisits can not be conducted\nremotely or virtually.\nClarification\nProtocol Amd 02\n206713\nAdded text in inclusion criteria\nrelated to pregnancy\nExclusion of participants with\nallergy/intolerance to the excipients\nof GSK3511294 in Section 6.1\nAirway reversibility\nor Airway\nhyperresponsiveness documented\nin the 24 months prior to Visit 2\ninstead of previous 12 months\nRevised QTc criteria\nText added for permission to\nreceive\nCOVID-19 Vaccine\nRemoved “troleandomycin” from\nprohibited medication\nLow dose ICS/LABA is not permitted\nas rescue medication.\nRescue\nmedication usage will be recorded in\nthe eDiary.\nCurrent “The procedures involved in\nthe Maximum Post-Bronchodilator\nMethod are those generated by the\nPulmonary Physiology\nSubcommittee “\nPreviously “The procedures involved\nin the Maximum Post-Bronchodilator\nMethod are those generated by the\nand not by Asthma Clinical\nResearch Network”\nCurrent “Details of reversibility\nprocedure mentioned in SRM”\nPreviously “Details of reversibility\nprocedure mentioned in in third\nparty vendor manual”\nSection 8.2.4.\nAsthma Daily\nSymptom\nDiary/Asthma Nightly\nSymptom Diary\n(ADSD/ANSD)\nSection 8.2.10.\nClarification of analysis populations\nwhich will be defined in SAP.\nCCI\nModified definition of SAE\nRemoved the requirement of SAE\nreporting in eCRF within 72 hours\nMinor editorial and document\nformatting revisions\nClarification\nAdded to align with clinical\nlaboratory worksheet."
https://cdn.clinicaltrials.gov/large-docs/32/NCT04719832/Prot_000.pdf

=-------------------------=

"Overall rationale for the current Amendment: The purpose of this amendment is to\ni) include the assessment of the efficacy of\nannual revaccinations with the RSVPreF3 OA\ninvestigational vaccine, in addition to the assessment of efficacy over 3 seasons after a\nsingle dose\nvaccination, and ii) add the evaluation of efficacy against each RSV subtype\nindependently as secondary confirmatory objective at the end of\nthe study, conditional to\nthe number of cases accrued.\nMoreover, the evaluation of efficacy against human\nmetapneumovirus (hMPV) will be upgraded to a secondary confirmatory objective.\nMinor editorial changes for consistency and clarity have also been made and\ntypographical errors have been corrected."
"url": "https://cdn.clinicaltrials.gov/large-docs/96/NCT04886596/Prot_000.pdf",
